EUCANCan was one of six projects funded under the Horizon2020 call SC1-BHC-05-2018 and received 5,999,453.75 EUR from the European Union’s Horizon 2020 research and innovation programme as well as funding from the Canadian Institutes of Health Research over the duration of four years, starting from January 1st 2019.

Horizon 2020

Horizon 2020 is the European Commission funding programme to support research and innovation in the European Union. This framework programme has a budget of about 77,028 billion euros for a 7 year period (2014-2020) to support research, technological development and relevant innovative initiatives.

Horizon 2020 groups, compliments and continues previous work achieved during the 7th Framework Programme for Research and Innovation (2007-2013), strengthens innovation actions from the Competitiveness and Innovation Framework Programme and the European Institute of Innovation and Technology actions.

Canadian Institutes of Health Research

The Canadian Institutes of Health Research (CIHR) is Canada’s federal funding agency for health research. Composed of 13 Institutes, we collaborate with partners and researchers to support the discoveries and innovations that improve our health and strengthen our health care system. CIHR was created in 2000 under the authority of the Canadian Institutes of Health Research Act. It is an independent agency and is accountable to Parliament through the Minister of Health. CIHR provides leadership and support to health researchers and trainees across Canada.

Network Partners

Six projects were selected for funding under the Horizon2020 call SC1-BHC-05-2018 “International flagship collaboration with Canada for human data storage, integration and sharing to enable personalized medicine approaches” designed to build a collaboration of stakeholders in Europe and Canada in the domain of repositories storing and sharing humanomics data that create a framework for long-term cooperation. The programme aimed to enhance and standardize data deposition, curation and exchange procedures thus ensuring better data reuse and increased benefit to the scientific communities worldwide.


Funding sum: € 6,531,275
Coordinator: Heidelberg University Hospital
ReCoDID (Integrated human data repositories for infectious disease-related international cohorts to foster personalized medicine approaches to infectious disease research) built on existing infrastructures and partnerships to develop a sustainable model for the storage, curation and analyses of the complex data sets collected by infectious disease (ID)-related cohorts. Drawing from best practice and governance elaborated for similar initiatives, the repository employed a federated model where a tiered permission system and cohort-specific hubs facilitate cohorts’ analysis of their own data, cross-cohort analyses and connections with the open science community within a clearly elaborated legal, ethical, and equitable framework.


Funding sum: €5,395,2923.50
Coordinator: University of Pompeu Fabra (UPF)
euCanSHare is an EU-Canada joint infrastructure for next-generation multi-Study Heart research. The 4-year Horizon 2020 project was coordinated by the University of Pompeu Fabra (UPF) in Spain, and included prestigious universities, research centres and SMEs in Canada and Europe (Germany, Italy, Netherlands, United Kingdom, Belgium, Spain, France, Austria and Finland). The project aimed at developing a translational research platform for cardiovascular data sharing between the European Union (EU) and Canada. Once established, researchers have benefited from a consolidated one-stop, integrated data shop to perform efficient and effective research based on data-driven approaches linking molecular, imaging, functional and clinical data. The end goal was tailor-made patient treatment and better cardiovascular disease outcomes. The project integrated more than 35 Canadian and European cohorts that make up over 1 million records. These cohorts included -omics (genomics, transcriptomics, metabolomics, just to name a few) cardiac imaging and clinical data.


Coordinator: European Molecular Biology Laboratory (EMBL)
CINECA (Common Infrastructure for National Cohorts in Europe, Canada, and Africa)’s vision has been a federated, cloud-enabled infrastructure making population-scale genomic and biomolecular data accessible across international borders, accelerating research and improving the health of individuals across continents. CINECA leveraged international investment in human cohort studies from Europe, Canada and Africa to deliver a paradigm shift of federated research and clinical applications. CINECA created one of the largest cross-continental implementations of human genetic and phenotypic data federation and interoperability with a focus on common (complex) disease.


Coordinator: University Medical Center Groningen (UMCG)
EUCAN-Connect (A federated FAIR platform enabling large-scale analysis of high-value cohort data connecting Europe and Canada in personalized health) enabled large-scale integrated cohort data analysis for personalized and preventive healthcare across EU and Canada. This was based on an open, scalable data platform for cohorts, researchers and networks, incorporating FAIR principles (Findable, Accessible, Interoperable, Reusable) for optimal reuse of existing data, and building on maturing federated technologies, with sensitive data kept locally and only results being shared and integrated, in line with key ELSI and governance guidelines.

iReceptor Plus

iReceptor Plus (Architecture and tools for the query of antibody and t-cell receptor sequencing data repositories for enabling improved personalized medicine and immunotherapy) aimed to facilitate the sharing of AIRR-seq data among multiple institutions for a better understanding of the causes of infectious and autoimmune diseases and cancer. Its consortium of researchers from EU and Canada addressed several key challenges to the optimal sharing of AIRR-seq data among public and industrial partners, such as patient privacy, intellectual property, data integration and harmonisation, to support early detection, identification of novel therapies and possibly reduce the social and economic burden of these diseases worldwide.